To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This study is a single-arm, randomized, open-label, multi-cohort Phase Ib clinical trial. The
experimental drug is TQB2858 Injection. The trial was divided into 3 cohorts. Cohort 1
included patients with advanced nasopharyngeal carcinoma who had previously failed
platinum-based chemotherapy and immune checkpoint inhibitors (programmed cell death protein 1
(PD-1)/ Programmed death-ligand 1 (PD-L1), etc.). Cohorts 2 and 3 were randomized into
patients with advanced, untreated nasopharyngeal carcinoma who had not received prior
systemic therapy. A total of 60-90 subjects are required.